Lei Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lei Shi has a total of 398 co-authors. Here are the top co-authors by number of shared publications:
Ling Liu
Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
14 shared publicationsZhi Yao
9 shared publicationsJie Yang
8 shared publications- Kai Zhang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
8 shared publications Kaiwen Bao
8 shared publicationsChunyong Zhang
7 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2280
Ganoderma lucidum Sporoderm-Broken Spore Powder (GLSP) Remodels the Gut Microbiota and Promotes Tryptophan-Derived Indole Metabolites to Maintain Intestinal Homeostasis
Ganoderma lucidum sporoderm-broken spore powder (GLSP) has been historically documented for its anti-aging and anti-tumor effects. Although several studies have reported that GLSP and related substance may improve physiological function by regulating the gut microbiota, the underlying mechanisms and their effect on intestinal function remains largely unknown. In this study, we comprehensively investigated the impact of dietary GLSP on intestinal epithelial dynamics and barrier function, assessed by single-cell RNA sequencing (scRNA-seq), using murine models spanning physiological homeostasis and DSS-induced intestinal injury. Our study reveals that GLSP protects intestinal epithelia against chemical and age-related barrier injury by promoting the coordinated expansion of stem/progenitor compartments and restoring both the mucus and physical barriers. Gut microbiota involvement was confirmed via antibiotic-treated mice and fecal microbiota transplantation (FMT). FMT from GLSP-diet donors successfully recapitulated the protective effects in gut microbiota-depleted recipient mice. Multi-omics integration of 16S rRNA sequencing and metabolomic profiling identified the enrichment of SCFA-producing genera, and previously unrecognized microbial metabolites, such as indole-2-carboxylic acid, 3-Methyloxindole, and 4-hydroxyindole. These microbial metabolites are likely to play an essential role in reprogramming the intestinal metabolome, particularly tryptophan–indole metabolic pathways, to mediate intestinal homeostasis. These findings provide novel insights and potential directions for the development of new drugs targeting intestinal injury.
- 7 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2280
Open AccessGanoderma lucidum Sporoderm-Broken Spore Powder (GLSP) Remodels the Gut Microbiota and Promotes Tryptophan-Derived Indole Metabolites to Maintain Intestinal Homeostasis
Ganoderma lucidum sporoderm-broken spore powder (GLSP) has been historically documented for its anti-aging and anti-tumor effects. Although several studies have reported that GLSP and related substance may improve physiological function by regulating the gut microbiota, the underlying mechanisms and their effect on intestinal function remains largely unknown. In this study, we comprehensively investigated the impact of dietary GLSP on intestinal epithelial dynamics and barrier function, assessed by single-cell RNA sequencing (scRNA-seq), using murine models spanning physiological homeostasis and DSS-induced intestinal injury. Our study reveals that GLSP protects intestinal epithelia against chemical and age-related barrier injury by promoting the coordinated expansion of stem/progenitor compartments and restoring both the mucus and physical barriers. Gut microbiota involvement was confirmed via antibiotic-treated mice and fecal microbiota transplantation (FMT). FMT from GLSP-diet donors successfully recapitulated the protective effects in gut microbiota-depleted recipient mice. Multi-omics integration of 16S rRNA sequencing and metabolomic profiling identified the enrichment of SCFA-producing genera, and previously unrecognized microbial metabolites, such as indole-2-carboxylic acid, 3-Methyloxindole, and 4-hydroxyindole. These microbial metabolites are likely to play an essential role in reprogramming the intestinal metabolome, particularly tryptophan–indole metabolic pathways, to mediate intestinal homeostasis. These findings provide novel insights and potential directions for the development of new drugs targeting intestinal injury.
- 20 July 2026
- Published by Elsevier in Molecular Cell
- Vol. 86 (15) , 2998-3016.e17
RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity
- 20 July 2026
- Published by Elsevier in Molecular Cell
- Vol. 86 (15) , 2998-3016.e17
RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity
- Open Access
- 16 July 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (9) , 113342
The DNTTIP1-PARP1 interaction orchestrates MiDAC recruitment and activity for NHEJ-mediated genome stability
- 16 July 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (9) , 113342
Open AccessThe DNTTIP1-PARP1 interaction orchestrates MiDAC recruitment and activity for NHEJ-mediated genome stability
- Open Access
- 18 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
DNA-PK-mediated CRTC2 phosphorylation promotes NHEJ and suppresses antitumor immunity via relocation to repair complexes
Genotoxic stress or exogenous DNA damage induces transcription arrest, enabling efficient DNA repair. Transcription activators directly participate in DNA damage repair (DDR), but the trans-regulatory mechanisms linking transcription and DDR remain elusive. Here we reveal that CRTC2 switches from a transcriptional coactivator to a DNA-damage responder. CRTC2 promotes non-homologous end joining (NHEJ) in vitro and in vivo. Mechanistically, PARP1 recruits CRTC2 to DNA breaks, where CRTC2 promotes DNA-PKcs enrichment and DNA-PK holoenzyme assembly, driving NHEJ. DNA-PK phosphorylates CRTC2 at Ser433, dissociating it from transcriptional complexes to suppress target gene transcription and promoting its incorporation into repair complexes, forming a positive feedback loop that enhances NHEJ. CRTC2 loss radiosensitizes liver cancer cells, potentiates irradiation-induced cGAS-STING activation, and promotes antitumor immunity and the abscopal effect. AAV8-mediated targeting of CRTC2 sensitizes tumors to radioimmunotherapy. Thus, CRTC2 couples transcriptional silencing to DNA repair, and its inhibition offers a promising strategy for radioimmunotherapy sensitization.
- 18 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDNA-PK-mediated CRTC2 phosphorylation promotes NHEJ and suppresses antitumor immunity via relocation to repair complexes
Genotoxic stress or exogenous DNA damage induces transcription arrest, enabling efficient DNA repair. Transcription activators directly participate in DNA damage repair (DDR), but the trans-regulatory mechanisms linking transcription and DDR remain elusive. Here we reveal that CRTC2 switches from a transcriptional coactivator to a DNA-damage responder. CRTC2 promotes non-homologous end joining (NHEJ) in vitro and in vivo. Mechanistically, PARP1 recruits CRTC2 to DNA breaks, where CRTC2 promotes DNA-PKcs enrichment and DNA-PK holoenzyme assembly, driving NHEJ. DNA-PK phosphorylates CRTC2 at Ser433, dissociating it from transcriptional complexes to suppress target gene transcription and promoting its incorporation into repair complexes, forming a positive feedback loop that enhances NHEJ. CRTC2 loss radiosensitizes liver cancer cells, potentiates irradiation-induced cGAS-STING activation, and promotes antitumor immunity and the abscopal effect. AAV8-mediated targeting of CRTC2 sensitizes tumors to radioimmunotherapy. Thus, CRTC2 couples transcriptional silencing to DNA repair, and its inhibition offers a promising strategy for radioimmunotherapy sensitization.
- Open Access
- 19 March 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (6)
A foundation model for nucleotide sequences
Foundation models have demonstrated exceptional performance across diverse downstream tasks. However, in genomics and transcriptomics, the integration of nucleotide sequences with their rich annotations remains underexplored, potentially limiting model generalizability across species and biological contexts. Here, we introduce OmniNA (Omni-applicable foundation model for nucleic acid), a self-supervised generative foundation model trained on 91.7 million nucleotide sequences and their associated annotations, totaling 1076.2 billion bases and 197 million words spanning diverse species. Unlike most existing approaches that focus solely on functional genomic element recognition, OmniNA jointly learns from both sequences and annotations, leveraging their complementarity to enhance semantic understanding and representation learning. We demonstrate that OmniNA captures sequence grammar and annotation semantics, facilitating robust transfer across nucleotide-level tasks. OmniNA can be fine-tuned under natural language paradigms and achieves state-of-the-art or competitive performance in 23 benchmarks, including sequence detection and species classification. Its learned representations also help reveal mutation effects on DNA and RNA processing. We release the model publicly as a community resource for genomics and transcriptomics research. OmniNA represents a step toward advancing foundational modeling by integrating annotation-aware learning, offering a powerful tool for genomics and transcriptomics research.
- 19 March 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (6)
Open AccessA foundation model for nucleotide sequences
Foundation models have demonstrated exceptional performance across diverse downstream tasks. However, in genomics and transcriptomics, the integration of nucleotide sequences with their rich annotations remains underexplored, potentially limiting model generalizability across species and biological contexts. Here, we introduce OmniNA (Omni-applicable foundation model for nucleic acid), a self-supervised generative foundation model trained on 91.7 million nucleotide sequences and their associated annotations, totaling 1076.2 billion bases and 197 million words spanning diverse species. Unlike most existing approaches that focus solely on functional genomic element recognition, OmniNA jointly learns from both sequences and annotations, leveraging their complementarity to enhance semantic understanding and representation learning. We demonstrate that OmniNA captures sequence grammar and annotation semantics, facilitating robust transfer across nucleotide-level tasks. OmniNA can be fine-tuned under natural language paradigms and achieves state-of-the-art or competitive performance in 23 benchmarks, including sequence detection and species classification. Its learned representations also help reveal mutation effects on DNA and RNA processing. We release the model publicly as a community resource for genomics and transcriptomics research. OmniNA represents a step toward advancing foundational modeling by integrating annotation-aware learning, offering a powerful tool for genomics and transcriptomics research.
- Open Access
- 3 February 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
LAP2α drives breast tumorigenesis by mitigating replication stress
Replication protein A (RPA) plays a vital role in replication stress response, with RPA-coated single-stranded DNA (ssDNA) acting as a critical platform for the coordination of the genome surveillance machinery. In previous studies, we reported that the lamin-associated protein LAP2α interacts physically with RPA, aiding its localization to damaged chromatin for genome protection. However, the significance of the LAP2α-mediated RPA deposition in tumor progression remains unclear. Here, we reveal that LAP2α promotes breast tumorigenesis by counteracting replication stress-induced DNA damage. Furthermore, we demonstrate that defects in RPA loading caused by LAP2α deficiency slow breast tumor growth and sensitize tumors to chemotherapeutic treatments. In addition, we found that LAP2α could directly stimulate the loading of RPA onto ssDNA. Collectively, our study characterizes a critical role of LAP2α-enhanced RPA loading in promoting breast tumorigenesis and positions the LAP2α-RPA complex as a promising target for therapeutic intervention in breast cancer.
- 3 February 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessLAP2α drives breast tumorigenesis by mitigating replication stress
Replication protein A (RPA) plays a vital role in replication stress response, with RPA-coated single-stranded DNA (ssDNA) acting as a critical platform for the coordination of the genome surveillance machinery. In previous studies, we reported that the lamin-associated protein LAP2α interacts physically with RPA, aiding its localization to damaged chromatin for genome protection. However, the significance of the LAP2α-mediated RPA deposition in tumor progression remains unclear. Here, we reveal that LAP2α promotes breast tumorigenesis by counteracting replication stress-induced DNA damage. Furthermore, we demonstrate that defects in RPA loading caused by LAP2α deficiency slow breast tumor growth and sensitize tumors to chemotherapeutic treatments. In addition, we found that LAP2α could directly stimulate the loading of RPA onto ssDNA. Collectively, our study characterizes a critical role of LAP2α-enhanced RPA loading in promoting breast tumorigenesis and positions the LAP2α-RPA complex as a promising target for therapeutic intervention in breast cancer.
- Open Access
- 18 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
ACSS1 co-opts acetyl-CoA metabolism to drive DNA repair and undermine radiotherapy efficacy in breast cancer
Breast cancer remains a leading cause of cancer-related mortality worldwide, with radiotherapy serving as a cornerstone of treatment. However, the development of radioresistance significantly compromises therapeutic efficacy and patient outcomes. Through integrative analysis of TCGA and GEO datasets combined with quantitative proteomics, we identified acetyl-CoA synthetase 1 (ACSS1) as a key driver of radioresistance in breast cancer. ACSS1 is aberrantly overexpressed in breast cancer and correlates with poor prognosis following radiotherapy. Functional studies revealed that overexpressed ACSS1 is able to enhance radioresistance both in vitro and in vivo. Mechanistically, ACSS1 amplifies the ionizing radiation (IR)-induced metabolic coupling of pyruvate with ROS for acetate synthesis, which fuels energy production and expands the nuclear acetyl-CoA pool, enabling histone acetylation at DNA damage sites. Such acetylation promotes chromatin relaxation at damage sites, facilitating the recruitment of homologous recombination (HR) repair machinery and ultimately leading to radioresistance. Our findings reveal that ACSS1 orchestrates acetyl-CoA-driven histone acetylation to enhance DNA repair efficiency, highlighting a metabolic-epigenetic crosstalk that sustains radioresistance in breast cancer. Targeting ACSS1 represents a promising therapeutic strategy to sensitize tumours to radiotherapy and improve clinical outcomes in breast cancer patients.
- 18 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessACSS1 co-opts acetyl-CoA metabolism to drive DNA repair and undermine radiotherapy efficacy in breast cancer
Breast cancer remains a leading cause of cancer-related mortality worldwide, with radiotherapy serving as a cornerstone of treatment. However, the development of radioresistance significantly compromises therapeutic efficacy and patient outcomes. Through integrative analysis of TCGA and GEO datasets combined with quantitative proteomics, we identified acetyl-CoA synthetase 1 (ACSS1) as a key driver of radioresistance in breast cancer. ACSS1 is aberrantly overexpressed in breast cancer and correlates with poor prognosis following radiotherapy. Functional studies revealed that overexpressed ACSS1 is able to enhance radioresistance both in vitro and in vivo. Mechanistically, ACSS1 amplifies the ionizing radiation (IR)-induced metabolic coupling of pyruvate with ROS for acetate synthesis, which fuels energy production and expands the nuclear acetyl-CoA pool, enabling histone acetylation at DNA damage sites. Such acetylation promotes chromatin relaxation at damage sites, facilitating the recruitment of homologous recombination (HR) repair machinery and ultimately leading to radioresistance. Our findings reveal that ACSS1 orchestrates acetyl-CoA-driven histone acetylation to enhance DNA repair efficiency, highlighting a metabolic-epigenetic crosstalk that sustains radioresistance in breast cancer. Targeting ACSS1 represents a promising therapeutic strategy to sensitize tumours to radiotherapy and improve clinical outcomes in breast cancer patients.
- Open Access
- 23 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models
Genome instability is most commonly caused by replication stress, which also renders cancer cells extremely vulnerable once their response to replication stress is impeded. Topoisomerase II binding protein 1 (TOPBP1), an allosteric activator of ataxia telangiectasia and Rad3-related kinase (ATR), coordinates ATR in replication stress response and has emerged as a potential therapeutic target for tumors. Here, we identify auranofin, the FDA-approved drug for rheumatoid arthritis, as a lead compound capable of binding to the BRCT 7–8 domains and blocking TOPBP1 interaction with PHF8 and FANCJ. The liquid-liquid phase separation of TOPBP1 is also disrupted by auranofin. Through targeting these TOPBP1-nucleated molecular machineries, auranofin leads to an accumulation of replication defects by impairing ATR activation and attenuating replication protein A loading on perturbed replication forks, and it shows significant anti–breast tumor activity in combination with a PARP inhibitor. This study provides mechanistic insights into how auranofin challenges replication integrity and expands the application of this FDA-approved drug in breast tumor intervention.
- 23 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
Open AccessAuranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models
Genome instability is most commonly caused by replication stress, which also renders cancer cells extremely vulnerable once their response to replication stress is impeded. Topoisomerase II binding protein 1 (TOPBP1), an allosteric activator of ataxia telangiectasia and Rad3-related kinase (ATR), coordinates ATR in replication stress response and has emerged as a potential therapeutic target for tumors. Here, we identify auranofin, the FDA-approved drug for rheumatoid arthritis, as a lead compound capable of binding to the BRCT 7–8 domains and blocking TOPBP1 interaction with PHF8 and FANCJ. The liquid-liquid phase separation of TOPBP1 is also disrupted by auranofin. Through targeting these TOPBP1-nucleated molecular machineries, auranofin leads to an accumulation of replication defects by impairing ATR activation and attenuating replication protein A loading on perturbed replication forks, and it shows significant anti–breast tumor activity in combination with a PARP inhibitor. This study provides mechanistic insights into how auranofin challenges replication integrity and expands the application of this FDA-approved drug in breast tumor intervention.
- 4 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (4) , 503-518
Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction
Background and Aims: An overactive inflammatory response and immune cell infiltration following myocardial infarction (MI) impair cardiac tissue repair. This study investigates the mechanistic role of the arachidonic acid (AA) metabolic cascade in mediating post-MI inflammation. Methods: Single-cell RNA-sequencing analysis was performed to characterize cardiac macrophage heterogeneity in post-MI mice. Metabolomic analyses were conducted to profile polyunsaturated fatty acid metabolites in both plasma from MI patients and cardiac tissue from infarcted mice to identify key factors influencing MI progression. Results: Leukotriene B4 (LTB4), an AA metabolite, was consistently elevated in MI patients and mouse models, demonstrating significantly higher plasma concentrations in recurrent MI cases. Mechanistically, AA promotes nuclear translocation of protein phosphatase 5 (PP5), which subsequently dephosphorylates 5-lipoxygenase at Thr218, driving sustained LTB4 production. This process enhances CXCL13-mediated B-cell recruitment and amplifies inflammation through macrophage-B-cell crosstalk. Disruption of PP5 in mouse macrophages prevents these adverse changes. Conclusions: The findings elucidate the conserved role of 5-lipoxygenase phosphorylation regulated LTB4 levels in MI and identify PP5 as a potential therapeutic target for the treatment of MI.
- 4 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (4) , 503-518
Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction
Background and Aims: An overactive inflammatory response and immune cell infiltration following myocardial infarction (MI) impair cardiac tissue repair. This study investigates the mechanistic role of the arachidonic acid (AA) metabolic cascade in mediating post-MI inflammation. Methods: Single-cell RNA-sequencing analysis was performed to characterize cardiac macrophage heterogeneity in post-MI mice. Metabolomic analyses were conducted to profile polyunsaturated fatty acid metabolites in both plasma from MI patients and cardiac tissue from infarcted mice to identify key factors influencing MI progression. Results: Leukotriene B4 (LTB4), an AA metabolite, was consistently elevated in MI patients and mouse models, demonstrating significantly higher plasma concentrations in recurrent MI cases. Mechanistically, AA promotes nuclear translocation of protein phosphatase 5 (PP5), which subsequently dephosphorylates 5-lipoxygenase at Thr218, driving sustained LTB4 production. This process enhances CXCL13-mediated B-cell recruitment and amplifies inflammation through macrophage-B-cell crosstalk. Disruption of PP5 in mouse macrophages prevents these adverse changes. Conclusions: The findings elucidate the conserved role of 5-lipoxygenase phosphorylation regulated LTB4 levels in MI and identify PP5 as a potential therapeutic target for the treatment of MI.